认知康复和有氧运动用于进展性多发性硬化症患者的认知障碍 (CogEx):一个随机,盲目,假控制试验
Anthony Feinstein1, Maria Pia Amato2, Giampaolo Brichetto3
1Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
The Lancet. Neurology
|September 22, 2023
概括
在渐进的多发性硬化症患者中,认知康复和运动并没有改善处理速度. 需要进一步的研究,以确定干预措施是否可以产生与不干预相比有意义的改善.
科学领域:
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
- 临床试验 临床试验
背景情况:
- 认知功能障碍在多发性硬化症 (MS) 中很常见.
- 虽然认知康复和运动对复发性复发性多发性硬化症有好处,但它们对进展性多发性硬化症的影响尚不清楚.
- 这项研究研究了渐进性多发性硬化症患者的综合认知康复和运动.
研究的目的:
- 评估认知康复和运动对渐进性多发性硬化症处理速度的单独和综合影响.
- 为了评估一个12周的干预计划的有效性.
主要方法:
- 一个随机的,模拟受控试验 (CogEx) 涉及311名进展性多发性硬化症患者 (25-65岁,EDSS <7,处理速度受损).
- 参与者被分配到:认知康复 + 运动,认知康复 + 假运动,运动 + 假认知康复,或双假.
- 干预措施每周进行两次,持续12周,通过符号数字模式测试 (SDMT) 测量处理速度.
主要成果:
- 在12周的SDMT得分中,在任何组之间都没有观察到显著差异 (p=0.85).
- 认知康复加运动组与双虚假组相比,显示出 -1.30 (95% CI -3.75至1.16) 的非显著差异.
- 在所有组中报告了11起不良事件,运动加虚假认知康复组的发病率最高.
结论:
- 结合认知康复和运动并没有改善渐进性多发性硬化症的处理速度.
- 假干预表明了一些活动,这表明需要进行比较干预与非干预组的研究.
- 需要进一步的研究来确定有效的策略,以提高这个群体的处理速度.
更多相关视频
08:48Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
16.9K
05:54A Rehabilitation Program of Exoskeleton-assisted Body Weight-Supported Treadmill Training with Non-immersive Virtual Reality for Stroke Patients
Published on: May 16, 2025
254
相关概念视频
Cognitive Development During Adulthood
142
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
142
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
